Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074296 | 0.88 | MAPT (0.61) | SMN1; SMN2KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL6074493 | 0.82 | KMT2A (0.75) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL6073585 | 0.81 | ALDH1A1 (0.62) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL18530465 | 0.81 | SMN1; SMN2 (0.79) | SMN1; SMN2KMT2AMEN1LMNAALOX12 | |
| SCHEMBL6802799 | 0.79 | LMNA (0.61) | SMN1; SMN2KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL7529463 | 0.76 | TP53 (0.80) | SMN1; SMN2KMT2AMEN1LMNAALOX12 | |
| SCHEMBL5962533 | 0.76 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AMEN1LMNAALOX12 | |
| SCHEMBL7535714 | 0.76 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2AMEN1LMNAALOX12 | |
| SCHEMBL95715 | 0.76 | SMN1; SMN2 (0.71) | SMN1; SMN2KMT2AMEN1LMNAALOX12 | |
| SCHEMBL7528115 | 0.76 | SMN1; SMN2 (0.72) | SMN1; SMN2KMT2AMEN1LMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | SMN1; SMN2 3999/4885KMT2A 3638/4885MEN1 2224/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | SMN1; SMN2 3999/4885KMT2A 3638/4885MEN1 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.